The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core. Methods: The Core has supervised the acquisition, quality control, and analysis of longitudinal [ 18 F]fluorodeoxyglucose PET (FDG‐PET) data in approximately half of the ADNI cohort. In an “add on” study, approximately 100 subjects also underwent scanning with [ 11 C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG‐PET as a potential outcome measure in clinical trials. Results: ADNI data indicate that FDG‐PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [ 18 F]‐labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites. Conclusions: ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jacobson, N. S., & Truax, P. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.12 · Cited by 7,770
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Self-citationFrequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
Self-citation(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Self-citationFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“In comparison with APOE 34 noncarriers in the same subject group, APOE 34 carriers in the NC group had significantly lower CMRgl in several AD-affected regions, supporting previous findings from this group [6,7] and others [8,9].”
ResultSelf-citationCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“In comparison with APOE 34 noncarriers in the same subject group, APOE 34 carriers in the NC group had significantly lower CMRgl in several AD-affected regions, supporting previous findings from this group [6,7] and others [8,9].”
ResultAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Self-citationTwo-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., & Nordberg, A. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 617
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608
Self-citationSmall, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 2×
“Although the prevalence of PIB positivity is high, as shown above there is high congruence between PIB and CSF Ab measures [4].”
BackgroundSelf-citationPreclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain
Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T. E., Kilbourn, M. R., Skovronsky, D., & Kung, H. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065284 · Cited by 431
Self-citationLangbaum, J. B. S., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., Alexander, G. E., Foster, N. L., Weiner, M. W., Koeppe, R. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.072 · Cited by 279 · cited 1×
“SPM5 was used to generate statistical maps of between-group differences in regional-to-whole brain measurements of the cerebral metabolic rate for glucose (CMRgl) in probable AD, MCI, and normal control (NC) groups; correlations with categorical and continuous measurements of clinical disease severity; and differences…”
MethodSelf-citationReducing between scanner differences in multi-center PET studies
Joshi, A., Koeppe, R. A., & Fessler, J. A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.057 · Cited by 247
Self-citationChen, K., Langbaum, J. B. S., Fleisher, A. S., Ayutyanont, N., Reschke, C., Lee, W., Liu, X., Bandy, D., Alexander, G. E., Thompson, P. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.064 · Cited by 169
Self-citationHua, X., Lee, S., Yanovsky, I., Leow, A. D., Chou, Y.-Y., Ho, A. J., Gutman, B., Toga, A. W., Jack, C. R., Bernstein, M. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.07.011 · Cited by 145
Self-citationFoster, N. L., Wang, A. Y., Taşdizen, T., Fletcher, P. T., Hoffman, J. M., & Koeppe, R. A. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.10.004 · Cited by 32
Self-citationTwo-year followup of amyloid deposition in patients with Alzheimer's disease
Grabowski, T. J. (2007) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70063-2 · Cited by 14
Research works printed but not linked: 1
- Mathis C.A., 2008, Longitudinal PIB measures in control, MCI, and AD subjects, J Nucl Med, 49, 35P
Cited by
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
“A similar approach has been used by others, most frequently in the use of “signature regions” for FDG data in AD [31-33].”
MethodSelf-citationIturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Self-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Metadata
- Authors
- Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2010-05
- Volume
- 6
- Issue
- 3
- Pages
- 221-229
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2044614452
- Cited by
- 533
- References
- 18
- FWCI
- 23.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institutes of Health (U01 AG024904)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.